The specific metabolites and genetic variants identified serve as robust biomarkers and offer valuable insights into the underlying pathophysiology of T2D, particularly highlighting the central role of the PI3K–AKT–mTORC1 signaling pathway. This evidence concerns the gene AKT1 and type 2 diabetes mellitus.